Seoyoung C Kim, Scd

List of Publications by Year
in descending order

194	7,892	53660 45	64668 79
papers	citations	h-index	g-index

200	200	200	10021
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Association Between Inflammation, Incident Heart Failure, and Heart Failure Subtypes in Patients With Rheumatoid Arthritis. Arthritis Care and Research, 2023, 75, 1036-1045.	1.5	8
2	Development of a Medicare Claimsâ€“Based Model to Predict Persistent Highâ€Dose Opioid Use After Total Knee Replacement. Arthritis Care and Research, 2022, 74, 1342-1348.	1.5	1
3	Risk of Hospitalization for Serious Infection After Initiation of Ustekinumab or Other Biologics in Patients With Psoriasis or Psoriatic Arthritis. Arthritis Care and Research, 2022, 74, 1792-1805.	1.5	22
4	Secular Trends in the Pharmacologic Treatment of Osteoporosis and Malignancy-Related Bone Disease from 2009 to 2020. Journal of General Internal Medicine, 2022, 37, 1917-1924.	1.3	5
5	Emulation of a randomized controlled trial in ulcerative colitis with <scp>US</scp> and French claims data: Infliximab with thiopurines compared to infliximab monotherapy. Pharmacoepidemiology and Drug Safety, 2022, 31, 167-175.	0.9	5
6	Risk of Serious Infections With Vedolizumab Versus Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology, 2022, 20, 314-324.e16.	2.4	27
7	Sodiumâ€“Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease. Annals of Internal Medicine, 2022, 175, W4.	2.0	0
8	Sodiumâ€“Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease. Annals of Internal Medicine, 2022, 175, W4-W5.	2.0	0
9	Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study. Annals of the Rheumatic Diseases, 2022, 81, 798-804.	0.5	76
10	Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis. Cardiovascular Diabetology, 2022, 21, 47.	2.7	49
11	Accuracy of identifying diagnosis of moderate to severe chronic kidney disease in administrative claims data. Pharmacoepidemiology and Drug Safety, 2022, 31, 467-475.	0.9	21
12	Decreased risk of treatment failure with vedolizumab and thiopurines combined compared with vedolizumab monotherapy in Crohnâ€™s disease. Gut, 2022, 71, 1781-1789.	6.1	11
13	Combined Conventional Synthetic Disease Modifying Therapy vs. Infliximab for Rheumatoid Arthritis: Emulating a Randomized Trial in Observational Data. Clinical Pharmacology and Therapeutics, 2022, 112, 836-845.	2.3	0
14	Tofacitinib and Risk of Malignancy: Results From the Safety of Tofacitinib in Routine Care Patients With Rheumatoid Arthritis (STARâ€RA) Study. Arthritis and Rheumatology, 2022, 74, 1648-1659.	2.9	31
15	Cardiovascular and mortality risk with intravitreal vascular endothelial growth factor inhibitor in patients with diabetic retinopathy. Ophthalmology Retina, 2022, , .	1.2	1
16	Predictors of Treatment Change Among Patients with Rheumatoid Arthritis Treated with TNF Inhibitors as First-Line Biologic Agent in the USA: A Cohort Study from Longitudinal Electronic Health Records. BioDrugs, 2022, 36, 521-535.	2.2	0
17	Cardiovascular Risks of Hydroxychloroquine vs Methotrexate in Patients With RheumatoidÂArthritis. Journal of the American College of Cardiology, 2022, 80, 36-46.	1.2	17
18	Tuberculosis risk with biologics by screening-guided preventive strategy in rheumatoid arthritis under intermediate tuberculosis burden. Rheumatology, 2021, 60, 2755-2764.	0.9	2

#	Article	IF	Citations
19	Dopamine dysregulation in psychotic relapse after antipsychotic discontinuation: an [18F]DOPA and [11C]raclopride PET study in first-episode psychosis. Molecular Psychiatry, 2021, 26, 3476-3488.	4.1	15
20	Risk of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Addition of SGLT2 Inhibitors Versus Sulfonylureas to Baseline GLP-1RA Therapy. Circulation, 2021, 143, 770-779.	1.6	47
21	Trends in Utilization of Urateâ€Lowering Therapies Following the US Food and Drug Administrationâ€™s Boxed Warning on Febuxostat. Arthritis and Rheumatology, 2021, 73, 542-543.	2.9	10
22	Dupilumab and the risk of conjunctivitis and serious infection in patients with atopic dermatitis: A propensity scoreâ€“matched cohort study. Journal of the American Academy of Dermatology, 2021, 84, 300-311.	0.6	20
23	The relationship between grey matter volume and striatal dopamine function in psychosis: a multimodal 18F-DOPA PET and voxel-based morphometry study. Molecular Psychiatry, 2021, 26, 1332-1345.	4.1	23
24	Effects of Long-Acting Injectable Paliperidone Palmitate on Clinical and Functional Outcomes in Patients With Schizophrenia Based on Illness Duration. Journal of Clinical Psychiatry, 2021, 82, .	1.1	15
25	Prevalence, incidence and cause-specific mortality of rheumatoid arthritisâ€“associated interstitial lung disease among older rheumatoid arthritis patients. Rheumatology, 2021, 60, 3689-3698.	0.9	43
26	The sequence of disease-modifying anti-rheumatic drugs: pathways to and predictors of tocilizumab monotherapy. Arthritis Research and Therapy, 2021, 23, 26.	1.6	7
27	Increased Risk of Psychopathological Abnormalities in Subjects With Unilateral Hearing Loss: A Cross-Sectional Study. Clinical and Experimental Otorhinolaryngology, 2021, 14, 82-87.	1.1	6
28	Risk of venous thromboembolism associated with tofacitinib in patients with rheumatoid arthritis: a population-based cohort study. Rheumatology, 2021, 61, 121-130.	0.9	41
29	Validation of claimsâ€based algorithms to identify patients with psoriasis. Pharmacoepidemiology and Drug Safety, 2021, 30, 868-874.	0.9	3
30	Updated Assessment of Cardiovascular Risk in Older Patients With Gout Initiating Febuxostat Versus Allopurinol. Journal of the American Heart Association, 2021, 10, e020045.	1.6	9
31	Incidence of Venous Thromboembolism in Patients With Dermatologist-Diagnosed Chronic Inflammatory Skin Diseases. JAMA Dermatology, 2021, 157, 805.	2.0	21
32	Predicting Response to Tocilizumab Monotherapy in Rheumatoid Arthritis: A Real-world Data Analysis Using Machine Learning. Journal of Rheumatology, 2021, 48, 1364-1370.	1.0	13
33	Temporal Trends in Prescribing of Bone-Directed Therapies in the United States, 2009â€“2020. Journal of the Endocrine Society, 2021, 5, A250-A250.	0.1	1
34	Knee osteonecrosis incidence from two real-world data sources. Osteoarthritis and Cartilage Open, 2021, 3, 100169.	0.9	2
35	Comparative Risk of Nonvertebral Fractures Among Patients With Rheumatoid Arthritis Treated With Biologic or Targeted Synthetic Diseaseâ€Modifying Antirheumatic Drugs. ACR Open Rheumatology, 2021, 3, 531-539.	0.9	7
36	Patient characteristics associated with use of TNF vs interleukin inhibitors as first-line biologic treatment for psoriatic arthritis. Journal of Managed Care & Specialty Pharmacy, 2021, 27, 1106-1117.	0.5	1

#	Article	IF	Citations
37	Validation of obesityâ€related diagnosis codes in claims data. Diabetes, Obesity and Metabolism, 2021, 23, 2623-2631.	2.2	20
38	Prescribing Trends of Antidiabetes Medications in Patients With Type 2 Diabetes and Diabetic Kidney Disease: A Cohort Study. Diabetes Care, 2021, 44, 2293-2301.	4.3	23
39	Cardiovascular risk associated with allopurinol vs. benzbromarone in patients with gout. European Heart Journal, 2021, 42, 4578-4588.	1.0	29
40	Sodiumâ€“Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease. Annals of Internal Medicine, 2021, 174, 1528-1541.	2.0	52
41	Identification of Acute Giant Cell Arteritis in Realâ€World Data Using Administrative Claimsâ€Based Algorithms. ACR Open Rheumatology, 2021, 3, 72-78.	0.9	4
42	The Patterns of Use of Medications for Inflammatory Bowel Disease During Pregnancy in the US and Sweden Are Changing. Inflammatory Bowel Diseases, 2021, 27, 1427-1434.	0.9	6
43	Risk of Non-Vertebral Fracture in Gout Compared to Rheumatoid Arthritis. Journal of Clinical Medicine, 2021, 10, 4655.	1.0	2
44	Associations of Clozapine Use With Psychosocial Functioning and Quality of Life in Patients With Schizophrenia: A Community-Based Cross-Sectional Study. Psychiatry Investigation, 2021, 18, 968-976.	0.7	0
45	Risk of venous thromboembolism associated with methotrexate versus hydroxychloroquine for rheumatoid arthritis: A propensity score-matched cohort study. Seminars in Arthritis and Rheumatism, 2021, 51, 1242-1250.	1.6	9
46	Association of Sodium-Glucose Cotransporterâ€“2 Inhibitors With Fracture Risk in Older Adults With Type 2 Diabetes. JAMA Network Open, 2021, 4, e2130762.	2.8	32
47	Comparative risks of cardiovascular disease events among SLE patients receiving immunosuppressive medications. Rheumatology, 2021, 60, 3789-3798.	0.9	5
48	Medication Burden and Prescribing Patterns in Patients on Hemodialysis in the USA, 2013â€“2017. American Journal of Nephrology, 2021, 52, 919-928.	1.4	6
49	Risk of Hospitalized Infection and Initiation of Abatacept Versus Tumor Necrosis Factor Inhibitors Among Patients With Rheumatoid Arthritis: A Propensity Scoreâ€“Matched Cohort Study. Arthritis Care and Research, 2020, 72, 9-17.	1.5	33
50	Risk of Serious Infection Among Initiators of Tumor Necrosis Factor Inhibitors Plus Methotrexate Versus Triple Therapy for Rheumatoid Arthritis: A Cohort Study. Arthritis Care and Research, 2020, 72, 1383-1391.	1.5	9
51	Methodologic considerations for noninterventional studies of switching from reference biologic to biosimilars. Pharmacoepidemiology and Drug Safety, 2020, 29, 757-769.	0.9	8
52	Assessment of body water distribution in patients with sepsis during fluid resuscitation using multi-frequency direct segmental bioelectrical impedance analysis. Clinical Nutrition, 2020, 39, 1826-1831.	2.3	13
53	Risk of exacerbation of pulmonary comorbidities in patients with rheumatoid arthritis after initiation of abatacept versus TNF inhibitors: A cohort study. Seminars in Arthritis and Rheumatism, 2020, 50, 401-408.	1.6	19
54	When Randomized Clinical Trials and Realâ€World Evidence Say the Same: Tocilizumab and Its Cardiovascular Safety. Arthritis and Rheumatology, 2020, 72, 4-6.	2.9	7

#	Article	IF	Citations
55	Mapping from the International Classification of Diseases (ICD) 9th to 10th Revision for Research in Biologics and Biosimilars Using Administrative Healthcare Data. Pharmacoepidemiology and Drug Safety, 2020, 29, 770-777.	0.9	8
56	Towards defining the safer use of opioids in rheumatology. Nature Reviews Rheumatology, 2020, 16, 71-72.	3.5	8
57	Risk of Diabetes Mellitus in Patients with Juvenile Idiopathic Arthritis. Journal of Rheumatology, 2020, 47, 1405-1408.	1.0	2
58	Validation of claimsâ€based algorithms for psoriatic arthritis. Pharmacoepidemiology and Drug Safety, 2020, 29, 404-408.	0.9	9
59	S203. EFFECT OF LONG-ACTING INJECTIONS OF PALIPERIDONE PALMITATE ON CLINICAL AND FUNCTIONAL OUTCOMES IN PATIENTS WITH SCHIZOPHRENIA BASED ON ILLNESS DURATION. Schizophrenia Bulletin, 2020, 46, S115-S116.	2.3	0
60	Risk of Uveitis in Patients With Inflammatory Bowel Disease on Immunosuppressive Drug Therapy. Crohn's & Colitis 360, 2020, 2, .	0.5	5
61	Risk of Incident Type 2 Diabetes Mellitus Among Patients With Rheumatoid Arthritis: A Populationâ€Based Cohort Study. Arthritis Care and Research, 2020, 72, 1248-1256.	1.5	12
62	Use of biologic or targeted-synthetic disease-modifying anti-rheumatic drugs and risk of diabetes treatment intensification in patients with rheumatoid arthritis and diabetes mellitus. Rheumatology Advances in Practice, 2020, 4, rkaa027.	0.3	10
63	Real-world patterns of pegloticase use for treatment of gout: descriptive multidatabase cohort study. BMJ Open, 2020, 10, e041167.	0.8	2
64	2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis and Rheumatology, 2020, 72, 879-895.	2.9	302
65	2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Care and Research, 2020, 72, 744-760.	1.5	420
66	Validation of claims-based algorithms to identify interstitial lung disease in patients with rheumatoid arthritis. Seminars in Arthritis and Rheumatism, 2020, 50, 592-597.	1.6	16
67	Optimum Designs for Large Database Research in Musculoskeletal Pain Management. Journal of Bone and Joint Surgery - Series A, 2020, 102, 54-58.	1.4	12
68	Shift From Adalimumab Originator to Biosimilars in Denmark. JAMA Internal Medicine, 2020, 180, 902.	2.6	57
69	Methodological Challenges in Conducting Large-Scale Real-World Data Analyses on Opioid Use in Musculoskeletal Disorders. Journal of Bone and Joint Surgery - Series A, 2020, 102, 10-14.	1.4	10
70	Predicting Remission Among Patients With Rheumatoid Arthritis Starting Tocilizumab Monotherapy: Model Derivation and Remission Score Development. ACR Open Rheumatology, 2020, 2, 65-73.	0.9	7
71	Utilization and Treatment Costs of Tumor Necrosis Factor Inhibitors After the Introduction of Biosimilar Infliximab in the United States. Arthritis and Rheumatology, 2020, 72, 1036-1038.	2.9	19
72	Risk of admission to hospital for serious infection after initiating tofacitinib versus biologic DMARDs in patients with rheumatoid arthritis: a multidatabase cohort study. Lancet Rheumatology, The, 2020, 2, e84-e98.	2.2	45

#	Article	IF	Citations
73	Risk of Inflammatory Arthritis After a New Diagnosis of Hidradenitis Suppurativa. JAMA Dermatology, 2020, 156, 342.	2.0	16
74	Risk of Cataract Surgery and Age-Related Macular Degeneration After Initiation of Denosumab vs Zoledronic Acid for Osteoporosis: A Multi-Database Cohort Study. Drugs and Aging, 2020, 37, 311-320.	1.3	3
75	Comparative Risk of Diabetes Mellitus in Patients With Rheumatoid Arthritis Treated With Biologic or Targeted Synthetic Diseaseâ€Modifying Drugs: A Cohort Study. ACR Open Rheumatology, 2020, 2, 222-231.	0.9	10
76	Risk of Incident Atrial Fibrillation With Zoledronic Acid Versus Denosumab: A Propensity Scoreâ€“Matched Cohort Study. Journal of Bone and Mineral Research, 2020, 36, 52-60.	3.1	15
77	Relationship of Change in Plasma Clozapine/N-desmethylclozapine Ratio with Cognitive Performance in Patients with Schizophrenia. Psychiatry Investigation, 2020, 17, 1158-1165.	0.7	7
78	Gout, Hyperuricemia, and Crystalâ€Associated Disease Network Consensus Statement Regarding Labels and Definitions for Disease Elements in Gout. Arthritis Care and Research, 2019, 71, 427-434.	1.5	73
79	Cardiovascular Safety of Urate Lowering Therapies. Current Rheumatology Reports, 2019, 21, 48.	2.1	11
80	Association of Preoperative Opioid Use With Mortality and Short-term Safety Outcomes After Total Knee Replacement. JAMA Network Open, 2019, 2, e198061.	2.8	48
81	Assessment for Perioperative Hyperglycemia Prior to Total Joint Replacement in Patients With and Without Diabetes. JAMA Network Open, 2019, 2, e1910589.	2.8	2
82	Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout. Annals of the Rheumatic Diseases, 2019, 78, 1592-1600.	0.5	72
83	Association of Geography and Access to Health Care Providers With Longâ€Term Prescription Opioid Use inÂMedicare Patients With Severe Osteoarthritis: AÂCohortÂStudy. Arthritis and Rheumatology, 2019, 71, 712-721.	2.9	26
84	Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study. Annals of the Rheumatic Diseases, 2019, 78, 456-464.	0.5	139
85	Comparative Fracture Risks Among United States MedicaidÂEnrollees With and Those Without Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2019, 71, 1141-1146.	2.9	26
86	A tool for empirical equipoise assessment in multigroup comparative effectiveness research. Pharmacoepidemiology and Drug Safety, 2019, 28, 934-941.	0.9	6
87	Comparative cardiovascular risk of allopurinol versus febuxostat in patients with gout: a nation-wide cohort study. Rheumatology, 2019, 58, 2122-2129.	0.9	29
88	Fracture Risk After Roux-en-Y Gastric Bypass vs Adjustable Gastric Banding Among Medicare Beneficiaries. JAMA Surgery, 2019, 154, 746.	2.2	36
89	Risk of Serious Infection in Patients Receiving Systemic Medications for the Treatment of Psoriasis. JAMA Dermatology, 2019, 155, 1142.	2.0	51
90	Cardiovascular Outcomes of Calcium-Free vs Calcium-Based Phosphate Binders in Patients 65 Years or Older With End-stage Renal Disease Requiring Hemodialysis. JAMA Internal Medicine, 2019, 179, 741.	2.6	27

#	Article	IF	Citations
91	Association of Ustekinumab vs TNF Inhibitor Therapy With Risk of Atrial Fibrillation and Cardiovascular Events in Patients With Psoriasis or Psoriatic Arthritis. JAMA Dermatology, 2019, 155, 700.	2.0	43
92	Risk of malignancy associated with use of tocilizumab versus other biologics in patients with rheumatoid arthritis: A multi-database cohort study. Seminars in Arthritis and Rheumatism, 2019, 49, 222-228.	1.6	42
93	Use of prescription opioids among patients with rheumatic diseases compared to patients with hypertension in the USA: a retrospective cohort study. BMJ Open, 2019, 9, e027495.	0.8	25
94	Fracture Risk After Initiation of Use of Canagliflozin. Annals of Internal Medicine, 2019, 171, 80.	2.0	9
95	FRI0119â€…PREDICTING REMISSION AMONG PATIENTS WITH RHEUMATOID ARTHRITIS STARTING TOCILIZUMAB MONOTHERAPY: MODEL DERIVATION AND VALIDATION USING CONVENTIONAL REGRESSION AND MACHINE LEARNING. , 2019, , .		0
96	FRAILTY AND THE COMPARATIVE EFFECTIVENESS AND SAFETY OF SGLT2I AND DPP4I IN OLDER ADULTS WITH TYPE 2 DIABETES. Innovation in Aging, 2019, 3, S582-S582.	0.0	1
97	FRAILTY AND THE COMPARATIVE EFFECTIVENESS AND SAFETY OF SGLT2I AND GLP1-RA IN OLDER ADULTS WITH TYPE 2 DIABETES. Innovation in Aging, 2019, 3, S582-S582.	0.0	0
98	Fracture Risk After Initiation of Use of Canagliflozin. Annals of Internal Medicine, 2019, 170, 155.	2.0	81
99	Frontostriatal functional connectivity and striatal dopamine synthesis capacity in schizophrenia in terms of antipsychotic responsiveness: an [¹⁸F]DOPA PET and fMRI study. Psychological Medicine, 2019, 49, 2533-2542.	2.7	15
100	Comparative Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients Receiving Tofacitinib Versus Those Receiving Tumor Necrosis Factor Inhibitors: An Observational Cohort Study. Arthritis and Rheumatology, 2019, 71, 892-900.	2.9	81
101	Cardiovascular Risks of ProbenecidÂVersus Allopurinol in OlderÂPatients WithÂGout. Journal of the American College of Cardiology, 2018, 71, 994-1004.	1.2	69
102	No difference in cardiovascular risk of tocilizumab versus abatacept for rheumatoid arthritis: A multi-database cohort study. Seminars in Arthritis and Rheumatism, 2018, 48, 399-405.	1.6	37
103	The relationship between dopamine receptor blockade and cognitive performance in schizophrenia: a [11C]-raclopride PET study with aripiprazole. Translational Psychiatry, 2018, 8, 87.	2.4	28
104	Racial/ethnic variation and risk factors for allopurinol-associated severe cutaneous adverse reactions: a cohort study. Annals of the Rheumatic Diseases, 2018, 77, annrheumdis-2017-212905.	0.5	29
105	Comparative Cardiovascular Risk of Abatacept and Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis With and Without Diabetes Mellitus: A Multidatabase Cohort Study. Journal of the American Heart Association, 2018, 7, .	1.6	55
106	Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study. BMJ: British Medical Journal, 2018, 360, k119.	2.4	132
107	Identification of monosodium urate crystal deposits in patients with asymptomatic hyperuricemia using dual-energy CT. RMD Open, 2018, 4, e000593.	1.8	33
108	Practice Pattern of Hepatitis B Testing in Rheumatoid Arthritis Patients: A Crossâ€National Comparison Between the US and Taiwan. Arthritis Care and Research, 2018, 70, 30-38.	1.5	10

#	Article	IF	Citations
109	Patterns of Systemic Treatment for Psoriatic Arthritis in the US: 2004-2015. Arthritis Care and Research, 2018, 70, 791-796.	1.5	13
110	Asymptomatic hyperuricemia and coronary flow reserve in patients with metabolic syndrome. BMC Rheumatology, 2018, 2, 17.	0.6	6
111	S156. FRONTO-STRIATAL FUNCTIONAL CONNECTIVITY AND STRIATAL DOPAMINE CAPACITY IN TREATMENT-RESPONSIVE AND REFRACTORY SCHIZOPHRENIA. Schizophrenia Bulletin, 2018, 44, S386-S386.	2.3	0
112	Change in Cognitive Function after Antipsychotics Treatment : A Pilot Study of Long-Acting Injectable versus Oral Form. Korean Journal of Schizophrenia Research, 2018, 21, 74.	0.3	0
113	Cardiovascular (CV) Risk after Initiation of Abatacept versus TNF Inhibitors in Rheumatoid Arthritis Patients with and without Baseline CV Disease. Journal of Rheumatology, 2018, 45, 1240-1248.	1.0	45
114	Cardiovascular Safety of Biologics and JAK Inhibitors in Patients with Rheumatoid Arthritis. Current Rheumatology Reports, 2018, 20, 42.	2.1	23
115	Association of Osteoporosis Medication Use After Hip Fracture With Prevention of Subsequent Nonvertebral Fractures. JAMA Network Open, 2018, 1, e180826.	2.8	64
116	Association between inflammation and systolic blood pressure in RA compared to patients without RA. Arthritis Research and Therapy, 2018, 20, 107.	1.6	18
117	Risk of human papillomavirus infection in women with rheumatic disease: cervical cancer screening and prevention. Rheumatology, 2018, 57, v26-v33.	0.9	12
118	Assessment of Cardiovascular Risk in Older Patients With Gout Initiating Febuxostat Versus Allopurinol. Circulation, 2018, 138, 1116-1126.	1.6	108
119	Assessment of coronary vascular function with cardiac PET in relation to serum uric acid. PLoS ONE, 2018, 13, e0192788.	1.1	4
120	Association of Medicare's Bundled Payment Reform With Changes in Use of Vitamin D Among Patients Receiving Maintenance Hemodialysis: An Interrupted Time-Series Analysis. American Journal of Kidney Diseases, 2018, 72, 178-187.	2.1	15
121	An evaluation of longitudinal changes in serum uric acid levels and associated risk of cardio-metabolic events and renal function decline in gout. PLoS ONE, 2018, 13, e0193622.	1.1	33
122	Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis: A Multiâ€Ðatabase Cohort Study. Arthritis and Rheumatology, 2017, 69, 1154-1164.	2.9	160
123	Fracture Risk After Bariatric Surgery: Rouxâ€enâ€Y Gastric Bypass Versus Adjustable Gastric Banding. Journal of Bone and Mineral Research, 2017, 32, 1229-1236.	3.1	106
124	Patterns and predictors of persistent opioid use following hip or knee arthroplasty. Osteoarthritis and Cartilage, 2017, 25, 1399-1406.	0.6	139
125	Antibiotic Use in Children â€“ A Cross-National Analysis of 6 Countries. Journal of Pediatrics, 2017, 182, 239-244.e1.	0.9	90
126	Alendronate and Hip Fracture in Patients Using Glucocorticoids. JAMA - Journal of the American Medical Association, 2017, 318, 1711.	3.8	0

#	Article	IF	Citations
127	Gout and the Risk of Non-vertebral Fracture. Journal of Bone and Mineral Research, 2017, 32, 230-236.	3.1	25
128	Comparative Rates of Serious Infections Among Patients With Systemic Lupus Erythematosus Receiving Immunosuppressive Medications. Arthritis and Rheumatology, 2017, 69, 387-397.	2.9	65
129	Gout and Risk of Fracture in Women: A Prospective Cohort Study. Arthritis and Rheumatology, 2017, 69, 422-428.	2.9	35
130	Comparative Safety and Effectiveness of Denosumab Versus Zoledronic Acid in Patients With Osteoporosis: A Cohort Study. Journal of Bone and Mineral Research, 2017, 32, 611-617.	3.1	44
131	Risk of serious infections associated with use of immunosuppressive agents in pregnant women with autoimmune inflammatory conditions: cohort study. BMJ: British Medical Journal, 2017, 356, j895.	2.4	50
132	Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2017, Volume 10, 123-139.	1.1	81
133	Factors associated with initial or subsequent choice of biologic disease-modifying antirheumatic drugs for treatment of rheumatoid arthritis. Arthritis Research and Therapy, 2017, 19, 159.	1.6	37
134	Temporal Trends in Use of Biologic DMARDs for Rheumatoid Arthritis in the United States: A Cohort Study of Publicly and Privately Insured Patients. Journal of Managed Care & Specialty Pharmacy, 2017, 23, 809-814.	0.5	30
135	Brief Report: Patterns and Secular Trends in Use of Immunomodulatory Agents During Pregnancy in Women With Rheumatic Conditions. Arthritis and Rheumatology, 2016, 68, 1183-1189.	2.9	27
136	Tumor Necrosis Factor-Î± Inhibitor Use and the Risk of Incident Hypertension in Patients with Rheumatoid Arthritis. Epidemiology, 2016, 27, 414-422.	1.2	18
137	Identification of smoking using Medicare data - a validation study of claims-based algorithms. Pharmacoepidemiology and Drug Safety, 2016, 25, 472-475.	0.9	55
138	Validation of claimsâ€based algorithms for gout flares. Pharmacoepidemiology and Drug Safety, 2016, 25, 820-826.	0.9	15
139	Potential confounding in colchicine and cardiovascular disease study. Annals of the Rheumatic Diseases, 2016, 75, e27-e27.	0.5	1
140	Response to: â€˜Effects of colchicine on risk of cardiovascular events among patients with gout: as evidence accrues, is it time for a randomized trial?â€™ by Giannopoulos and Deftereos. Annals of the Rheumatic Diseases, 2016, 75, e29-e29.	0.5	1
141	Bioequivalence of Biosimilar Tumor Necrosis Factor-Î± Inhibitors Compared With Their Reference Biologics. Annals of Internal Medicine, 2016, 165, 565.	2.0	52
142	Racial disparities in the risk of Stevensâ€“Johnson Syndrome and toxic epidermal necrolysis as urate-lowering drug adverse events in the United States. Seminars in Arthritis and Rheumatism, 2016, 46, 253-258.	1.6	43
143	Biologic Diseaseâ€Modifying Antirheumatic Drugs and Risk of Highâ€Grade Cervical Dysplasia and Cervical Cancer in Rheumatoid Arthritis: A Cohort Study. Arthritis and Rheumatology, 2016, 68, 2106-2113.	2.9	19
144	Cross-National Variation in Glycemic Control and Diabetes-Related Distress Among East Asian Patients Using Insulin: Results from the MOSAIc Study. Diabetes Therapy, 2016, 7, 349-360.	1.2	5

#	Article	IF	Citations
145	Impact of the U.S. Food and Drug Administration's Safety-Related Announcements on the Use of Bisphosphonates After Hip Fracture. Journal of Bone and Mineral Research, 2016, 31, 1536-1540.	3.1	90
146	Effects of colchicine on risk of cardiovascular events and mortality among patients with gout: a cohort study using electronic medical records linked with Medicare claims. Annals of the Rheumatic Diseases, 2016, 75, 1674-1679.	0.5	113
147	Risk of incident atrial fibrillation in gout: a cohort study. Annals of the Rheumatic Diseases, 2016, 75, 1473-1478.	0.5	40
148	Geographic patterns in patient demographics and insulin use in 18 countries, a global perspective from the multinational observational study assessing insulin use: understanding the challenges associated with progression of therapy (MOSAIc). BMC Endocrine Disorders, 2015, 15, 46.	0.9	39
149	Uptake of the First Biosimilar Infliximab since its Approval in South Korea. Arthritis and Rheumatology, 2015, 68, n/a-n/a.	2.9	12
150	Human Papillomavirus Vaccine Uptake among Individuals with Systemic Inflammatory Diseases. PLoS ONE, 2015, 10, e0117620.	1.1	14
151	Patterns of health care utilization related to initiation of amitriptyline, duloxetine, gabapentin, or pregabalin in fibromyalgia. Arthritis Research and Therapy, 2015, 17, 18.	1.6	15
152	Effects of Xanthine Oxidase Inhibitors on Cardiovascular Disease in Patients with Gout: AÂCohort Study. American Journal of Medicine, 2015, 128, 653.e7-653.e16.	0.6	75
153	Use of Osteoporosis Medications after Hospitalization for Hip Fracture: A Cross-national Study. American Journal of Medicine, 2015, 128, 519-526.e1.	0.6	98
154	Risk of Venous Thromboembolism in Patients with Rheumatoid Arthritis: Initiating Disease-Modifying Antirheumatic Drugs. American Journal of Medicine, 2015, 128, 539.e7-539.e17.	0.6	30
155	Association Between Lipid Levels and Major Adverse Cardiovascular Events in Rheumatoid Arthritis Compared to Nonâ€“Rheumatoid Arthritis Patients. Arthritis and Rheumatology, 2015, 67, 2004-2010.	2.9	57
156	Reductions in Use of Colchicine after FDA Enforcement of Market Exclusivity in a Commercially Insured Population. Journal of General Internal Medicine, 2015, 30, 1633-1638.	1.3	18
157	An external validation study reporting poor correlation between the claims-based index for rheumatoid arthritis severity and the disease activity score. Arthritis Research and Therapy, 2015, 17, 83.	1.6	13
158	Serious Infections Among Adult Medicaid Beneficiaries With Systemic Lupus Erythematosus and Lupus Nephritis. Arthritis and Rheumatology, 2015, 67, 1577-1585.	2.9	177
159	Active-comparator design and new-user design in observational studies. Nature Reviews Rheumatology, 2015, 11, 437-441.	3.5	225
160	Risk of high-grade cervical dysplasia and cervical cancer in women with systemic inflammatory diseases: a population-based cohort study. Annals of the Rheumatic Diseases, 2015, 74, 1360-1367.	0.5	108
161	Risk of Incident Diabetes in Patients With Gout: A Cohort Study. Arthritis and Rheumatology, 2015, 67, 273-280.	2.9	49
162	Diseaseâ€Modifying Antirheumatic Drug Use and the Risk of Incident Hyperlipidemia in Patients With Early Rheumatoid Arthritis: A Retrospective Cohort Study. Arthritis Care and Research, 2015, 67, 457-466.	1.5	28

#	Article	IF	Citations
163	Dipeptidyl peptidase-4 inhibitors in type 2 diabetes may reduce the risk of autoimmune diseases: a population-based cohort study. Annals of the Rheumatic Diseases, 2015, 74, 1968-1975.	0.5	82
164	Patterns of Bisphosphonates Utilization in Patients under Age 45 in a Large Cohort of Commercial Insurance Beneficiaries in the United States. PLoS ONE, 2015, 10, e0115091.	1.1	6
165	Bisphosphonates and Risk of Cardiovascular Events: A Meta-Analysis. PLoS ONE, 2015, 10, e0122646.	1.1	94
166	Behavioral and Clinical Factors Associated with Self-Reported Abnormal Papanicolaou Tests in Rheumatoid Arthritis. Journal of Women's Health, 2014, 23, 771-776.	1.5	2
167	Dipeptidyl peptidase-4 inhibitors do not increase the risk of cardiovascular events in type 2 diabetes: a cohort study. Acta Diabetologica, 2014, 51, 1015-1023.	1.2	35
168	Relationships Between Driving Distance, Rheumatoid Arthritis Diagnosis, and Diseaseâ€Modifying Antirheumatic Drug Receipt. Arthritis Care and Research, 2014, 66, 1634-1643.	1.5	16
169	Should we target patients with autoimmune diseases for human papillomavirus vaccine uptake?. Expert Review of Vaccines, 2014, 13, 931-934.	2.0	9
170	Gout. Rheumatic Disease Clinics of North America, 2014, 40, 581-604.	0.8	83
171	Predictors of Stopping and Starting Diseaseâ€Modifying Antirheumatic Drugs for Rheumatoid Arthritis. Arthritis Care and Research, 2014, 66, 1152-1158.	1.5	13
172	Sociodemographic, Disease, Health System, and Contextual Factors Affecting the Initiation of Biologic Agents in Rheumatoid Arthritis: A Longitudinal Study. Arthritis Care and Research, 2014, 66, 980-989.	1.5	39
173	Editorial: Safety of Immunosuppressive Drugs in Pregnant Women With Systemic Inflammatory Diseases. Arthritis and Rheumatology, 2014, 66, 246-249.	2.9	10
174	The risk of atrial fibrillation in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2014, 73, 1091-1095.	0.5	34
175	Sociodemographics and epidemiology of serious infections requiring hospitalization among adults with systemic lupus erythematosus and lupus nephritis, 2000 to 2006. Arthritis Research and Therapy, 2014, 16, A37.	1.6	0
176	Serious infection incidence rates in pediatric systemic lupus erythematosus according to medication use. Arthritis Research and Therapy, 2014, 16, A39.	1.6	0
177	Clinical and Health Care Use Characteristics of Patients Newly Starting Allopurinol, Febuxostat, and Colchicine for the Treatment of Gout. Arthritis Care and Research, 2013, 65, 2008-2014.	1.5	24
178	Changes in Use of Diseaseâ€Modifying Antirheumatic Drugs for Rheumatoid Arthritis in the United States During 1983â€“2009. Arthritis Care and Research, 2013, 65, 1529-1533.	1.5	35
179	Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: A systematic review and meta-analysis. Journal of Bone and Mineral Research, 2013, 28, 1729-1737.	3.1	213
180	Severe Cutaneous Reactions Requiring Hospitalization in Allopurinol Initiators: A Populationâ€Based Cohort Study. Arthritis Care and Research, 2013, 65, 578-584.	1.5	79

#	Article	IF	Citations
181	Risk of Venous Thromboembolism in Patients With Rheumatoid Arthritis. Arthritis Care and Research, 2013, 65, 1600-1607.	1.5	108
182	Validation of claimsâ€based algorithms for identification of highâ€grade cervical dysplasia and cervical cancer. Pharmacoepidemiology and Drug Safety, 2013, 22, 1239-1244.	0.9	21
183	Clinical Characteristics and Medication Uses Among Fibromyalgia Patients Newly Prescribed Amitriptyline, Duloxetine, Gabapentin, or Pregabalin. Arthritis Care and Research, 2013, 65, 1813-1819.	1.5	27
184	Supplementing claims data with outpatient laboratory test results to improve confounding adjustment in effectiveness studies of lipid-lowering treatments. BMC Medical Research Methodology, 2012, 12, 180.	1.4	33
185	No differences in cancer screening rates in patients with rheumatoid arthritis compared to the general population. Arthritis and Rheumatism, 2012, 64, 3076-3082.	6.7	30
186	Effects of disease-modifying antirheumatic drugs on nonvertebral fracture risk in rheumatoid arthritis: A population-based cohort study. Journal of Bone and Mineral Research, 2012, 27, 789-796.	3.1	61
187	Validation of rheumatoid arthritis diagnoses in health care utilization data. Arthritis Research and Therapy, 2011, 13, R32.	1.6	184
188	Accuracy of identifying neutropenia diagnoses in outpatient claims data. Pharmacoepidemiology and Drug Safety, 2011, 20, 709-713.	0.9	8
189	Oral bisphosphonates and risk of subtrochanteric or diaphyseal femur fractures in a population-based cohort. Journal of Bone and Mineral Research, 2011, 26, 993-1001.	3.1	79
190	Comparative safety of nonsteroidal anti-inflammatory drugs. Nature Reviews Cardiology, 2011, 8, 193-195.	6.1	1
191	Hyperuricemia and coronary heart disease: A systematic review and metaâ€analysis. Arthritis Care and Research, 2010, 62, 170-180.	1.5	433
192	Tumor necrosis factor blockade and the risk of viral infection. Nature Reviews Rheumatology, 2010, 6, 165-174.	3.5	148
193	Risk of osteoporotic fracture in a large population-based cohort of patients with rheumatoid arthritis. Arthritis Research and Therapy, 2010, 12, R154.	1.6	176
194	Bisphosphonates and risk of atrial fibrillation: a meta-analysis. Arthritis Research and Therapy, 2010, 12, R30.	1.6	30